Risk Factors for PICC-Related Infection in 994 High-Risk Patients: The Role of Hb Levels and Sampling Frequency

June 23, 2026 updated by: Sawita Kanavitoon, Mahidol University

Risk Factors for PICC-Related Infection in 994 High-Risk Patients: The Role of Hb Levels and Sampling Frequency-A Retrospective Cohort Study

This retrospective cohort study aims to evaluate the incidence and clinical predictors of Central Line-Associated Bloodstream Infections (CLABSI) in patients receiving Peripherally Inserted Central Catheters (PICCs) via the Anesthesia Department.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

1239

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Thailand
    • Bangkok
      • Bangkok Noi, Bangkok, Thailand, 10700
        • Siriraj Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Critcally illed patient or patient with cancer who was inserted PICC line

Description

Inclusion Criteria:

  • Patient with PICC line more than 48 hours, performed by Anesthesia Department from January 2023 to December 2024

Exclusion Criteria:

  • Incomplete data
  • Patient with reported colonization of PICC line
  • Patient with unintended position of PICC line
  • Patient with any other central venous catheter besides PICC line
  • Patient with previously reported as CLABSI

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
non CLABSI
CLABSI
Patient with CLABSI
Other: Hemoglobin level
Hb ≤ 9.6 g/dL

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
rate of CLABSI
Time Frame: From January 2023 to December 2024
incidence of CLABSI
From January 2023 to December 2024

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Study the risk factors related to CLABSI, including clinical factors, comorbidities, indication for PICC, and laboratory.
Time Frame: From January 2023 to December 2024
To evaluate potential risk factors for CLABSI, baseline demographic, clinical, and procedural characteristics will be collected at PICC line insertion and analyzed using two aggregated formats: continuous variables will be reported as means (with SD) or medians (with IQR): age (years), weight (kg), height (m), combined BMI (kg/m^2), procedure duration (minutes), catheter indwelling time (days), hemoglobin (g/dL), and white blood cell counts (cells/µL). Categorical variables will be reported as percentages/proportions: sex, ICU admission, preprocedural antibiotics, procedure duration <60 minutes, indwelling time ≤6 weeks, comorbidities (immunocompromised, hypertension, liver disease, diabetes, oncologic/hematologic malignancies), and insertion indications (TPN, CMT, prolonged IV meds, frequent blood sampling, vasopressors). All variables will be analyzed via regression to identify independent predictors of CLABSI.
From January 2023 to December 2024

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mahidol University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2023

Primary Completion (Actual)

December 31, 2025

Study Completion (Actual)

April 1, 2026

Study Registration Dates

First Submitted

June 2, 2026

First Submitted That Met QC Criteria

June 23, 2026

First Posted (Actual)

June 30, 2026

Study Record Updates

Last Update Posted (Actual)

June 30, 2026

Last Update Submitted That Met QC Criteria

June 23, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Si327/2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe